ADAM10 and melanoma: To validate the ChIP-seq data, we performed chromatin immunoprecipitation experiments on the MITFHigh IGR37 and 501mel melanoma lines using an anti-MITF antibody, and then performed PCR assays using primers specific to the ADAM10 promoter region spanning the binding site identified in the ChIP-seq experiments.